FX.co ★ Cytokinetics: Phase 1 Study Of CK-4021586 Meets Primary And Secondary Objectives

Cytokinetics (CYTK) reported findings from its Phase 1 study of CK-4021586, also known as CK-586. The study successfully achieved its primary and secondary objectives, evaluating the safety, tolerability, and pharmacokinetics of both single and multiple oral doses of CK-586. The results encourage the progression of CK-586 to a Phase 2 trial in patients with heart failure with preserved ejection fraction (HFpEF), which is anticipated to commence in the fourth quarter of 2024.

"The data from this Phase 1 study confirm pre-clinical results showing that CK-586 directly reduces cardiac contractility at the sarcomere level. Notably, CK-586 demonstrated a predictable pharmacokinetic/pharmacodynamic (PK/PD) relationship and half-life, supporting a once-daily fixed dosing regimen for HFpEF patients," said Stuart Kupfer, Senior Vice President and Chief Medical Officer.